Substantial eGFR Declines After SGLT2 Start Track With Worse Early Outcomes in CKD

Initiating an SGLT2 inhibitor in a patient with chronic kidney disease often brings an expected early dip in estimated glomerular filtration rate. In this hospitalized CKD cohort, the important signal was not the dip itself, but the size of the decline: substantial falls in eGFR after treatment initiation were associated with increased short-term mortality.

The finding places a familiar class effect under a sharper clinical lens. SGLT2 inhibitors commonly trigger an early hemodynamic change at the glomerulus, a shift tied to reduced intraglomerular pressure and altered tubuloglomerular feedback. In routine outpatient care, that initial change is often accepted as part of the drug’s renal physiology. In hospitalized patients, especially those already carrying CKD, a larger-than-expected decline may mark a more fragile circulatory state, reduced renal reserve, or an intercurrent illness that leaves little tolerance for additional hemodynamic stress.

The Early eGFR Dip Cannot Be Read in Isolation

An early fall in eGFR after SGLT2 inhibitor initiation is not automatically a sign of drug toxicity. In many settings, the medication’s mechanism is precisely to produce a modest functional change before longer-term renal protection emerges. The problem begins when the decline is substantial enough to raise concern that the kidney is responding to something beyond the intended pharmacology.

In hospitalized patients with CKD, several processes can converge at once: volume depletion, infection, heart failure, reduced oral intake, diuretic exposure, hypotension, and acute kidney injury. A large drop in eGFR after starting an SGLT2 inhibitor may therefore function less like a harmless laboratory fluctuation and more like a bedside warning light. The association with short-term mortality suggests that the magnitude of renal function decline may identify patients who are already physiologically stressed, rather than those merely experiencing the expected class effect.

That distinction matters at the bedside. A clinician facing a marked eGFR fall soon after treatment initiation has to consider whether the drug is unmasking hemodynamic vulnerability or whether the decline reflects a broader acute process that is itself driving risk.

Mortality Signal Raises the Stakes for Inpatient Use

The title of the study frames the outcome plainly: substantial post-initiation eGFR declines were linked to increased short-term mortality in hospitalized CKD patients. Even without additional numerical detail, the clinical meaning is hard to miss. Short-term mortality in this setting is not a theoretical endpoint; it reflects the consequence of acute decompensation in a population already at high baseline risk.

A hospital stay changes the usual calculus for SGLT2 inhibitor management. These drugs are routinely used for cardiorenal benefit, but in acutely ill patients they must be placed against the realities of inpatient physiology. Renal perfusion can be unstable. Fluid balance can shift quickly. Blood pressure can fall. Glycosuria-related osmotic effects may be clinically relevant in someone with poor intake or concurrent diuretic therapy. A substantial eGFR decline in this context may be the first measurable sign that the kidney is not tolerating the current hemodynamic environment.

The biologic plausibility is strong. SGLT2 inhibitors lower intraglomerular pressure through tubuloglomerular feedback, which can be beneficial when the kidney is functioning in a stable outpatient state. In a hospitalized patient with CKD, the same mechanism may interact with reduced effective circulating volume or other acute insults. The renal lab signal then becomes a marker of vulnerability, and mortality risk rises because the underlying physiologic reserve is already thin.

Why the Hospital Setting Changes Interpretation

Outpatient prescribing of SGLT2 inhibitors usually occurs in a more controlled environment, where serial monitoring and longitudinal benefit can be weighed against the early creatinine or eGFR shift. Hospitalized patients are different. Their renal function may be changing hour by hour, and the context surrounding the medication start can be more complex than a single prescription decision suggests.

The study title places hospitalized CKD patients at the center, which is clinically important because CKD patients in the inpatient setting often sit at the intersection of multiple competing hazards. Some are admitted with decompensated heart failure, some with infection, some with progressive renal dysfunction, and some with metabolic derangements that complicate medication management. In such patients, a substantial eGFR decline after starting an SGLT2 inhibitor may not be a benign pharmacodynamic footnote. It may identify those who need immediate reassessment of volume status, blood pressure, concurrent diuretics, and overall hemodynamic stability.

This is where practical nephrology meets inpatient medicine. The lab trend is not merely a number to archive; it is a prompt to ask whether the patient can safely continue the drug in the current clinical state.

Monitoring Should Match the Risk Signal

The study’s main value is not a suggestion to avoid SGLT2 inhibitors wholesale in CKD. These agents remain central to cardiorenal care. The message is narrower and more urgent: substantial eGFR declines after initiation deserve attention, particularly in hospitalized patients, because they appear to identify a group with higher short-term mortality.

That means monitoring needs to be more than routine checkbox medicine. Renal function should be reviewed in relation to the patient’s volume status, hemodynamics, and concurrent therapies. A large early decline should trigger a search for reversible contributors rather than being dismissed as a predictable class effect. In the inpatient environment, the clinical question is not whether SGLT2 inhibitors can be useful—they can—but whether the patient in front of the clinician is stable enough to tolerate the expected hemodynamic shift without tipping into danger.

The signal also argues for tighter communication between nephrology, cardiology, and hospital medicine. SGLT2 inhibitor initiation in CKD is often driven by long-term organ protection, but short-term physiology can override long-term strategy in the acutely ill. When eGFR falls substantially after initiation, the right response is a careful reassessment of the patient’s immediate renal and circulatory status.

A Renal Marker With Bedside Consequences

The most clinically relevant feature of this study is its temporal focus. Mortality was not a distant endpoint buried in years of follow-up; it was short-term mortality, the kind of outcome that often tracks acute vulnerability. In that frame, a steep eGFR decline after SGLT2 inhibitor initiation looks less like a numeric quirk and more like a prognostic marker with immediate bedside consequences.

For hospitalized CKD patients, the message is direct: an eGFR drop after starting an SGLT2 inhibitor should not be ignored, especially when the decline is substantial. It should prompt a search for hemodynamic instability, acute kidney injury, or another driver of physiologic stress that may be doing the real damage.

What the abstract does not provide are the thresholds defining “substantial” decline, the exact mortality gradient, or the clinical context behind each admission. Those details will matter for translating the finding into practice. Until then, the central warning remains concrete: in hospitalized patients with CKD, a large early fall in eGFR after SGLT2 inhibitor initiation may mark a group at higher risk of dying soon after treatment begins.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by European Heart Journal.